WVE Wave Life Sciences Ltd

Price (delayed)

$6.13

Market cap

$1.18B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.05

Enterprise value

$650.41M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 23

Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using ...

Highlights
The equity has soared by 198% YoY
The quick ratio has soared by 72% QoQ
WVE's gross profit has soared by 68% since the previous quarter but it is down by 32% year-on-year
Wave Life Sciences's revenue has surged by 68% QoQ but it has decreased by 32% YoY

Key stats

What are the main financial stats of WVE

WVE stock price

How has the Wave Life Sciences stock price performed over time
Intraday
6.42%
1 week
-5.26%
1 month
-17.94%
1 year
-8.23%
YTD
-63.94%
QTD
-15.45%

Financial performance

How have Wave Life Sciences's revenue and profit performed over time
Revenue
$71.8M
Gross profit
$71.8M
Operating income
-$196.88M
Net income
-$183.59M
Gross margin
100%
Net margin
-255.7%
Wave Life Sciences's net margin has shrunk by 139% YoY but it has increased by 47% QoQ
The operating margin has plunged by 129% YoY but it has grown by 46% from the previous quarter
WVE's gross profit has soared by 68% since the previous quarter but it is down by 32% year-on-year
Wave Life Sciences's revenue has surged by 68% QoQ but it has decreased by 32% YoY

Price vs fundamentals

How does WVE's price correlate with its fundamentals

Growth

What is Wave Life Sciences's growth rate over time

Valuation

What is Wave Life Sciences stock price valuation
P/E
N/A
P/B
2.26
P/S
17.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.06
Wave Life Sciences's EPS has decreased by 42% YoY but it has increased by 13% from the previous quarter
The equity has soared by 198% YoY
The stock's price to book (P/B) is 66% less than its last 4 quarters average of 6.2
Wave Life Sciences's revenue has surged by 68% QoQ but it has decreased by 32% YoY
The P/S is 42% below the last 4 quarters average of 27.5 and 35% below the 5-year quarterly average of 24.7

Efficiency

How efficient is Wave Life Sciences business performance
Wave Life Sciences's ROS has plunged by 139% YoY but it has increased by 47% from the previous quarter
Wave Life Sciences's return on equity has increased by 34% YoY and by 34% QoQ
WVE's return on assets is up by 26% since the previous quarter but it is down by 15% year-on-year

Dividends

What is WVE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WVE.

Financial health

How did Wave Life Sciences financials performed over time
The total assets has soared by 102% year-on-year but it is down by 9% since the previous quarter
WVE's current ratio has soared by 74% since the previous quarter
Wave Life Sciences's debt is 97% lower than its equity
The equity has soared by 198% YoY
Wave Life Sciences's debt to equity has plunged by 79% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.